Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia 2Depression 2Tuberous Sclerosis 1Tourette Syndrome 1Tic Disorders 1Preleukemia 1Neurodevelopmental Disorders 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Hot Flashes 1Hematologic Diseases 1Glioblastoma 1Fragile X Syndrome 1DiGeorge Syndrome 1Cytopenia 1Breast Neoplasms 1Bone Marrow Diseases 1Autistic Disorder 1Autism Spectrum Disorder 1Attention Deficit Disorder with Hyperactivity 1Anxiety Disorders 1Anemia 122q11 Deletion Syndrome 1

Interventions

Temozolomide 264Radiotherapy 119Bevacizumab 105Magnetic Resonance Spectroscopy 59Radiation 47pembrolizumab 30Irinotecan 28Surgical Procedures, Operative 23Lomustine 21Specimen Handling 19Nivolumab 19Radiosurgery 18Carmustine 18Aminolevulinic Acid 16Erlotinib Hydrochloride 15Drug Therapy 15Blood Specimen Collection 14Radiotherapy, Intensity-Modulated 13O(6)-benzylguanine 13Chemotherapy, Adjuvant 13Carboplatin 13Filgrastim 11Cyclophosphamide 11sargramostim 10poly ICLC 10atezolizumab 10Thalidomide 10Etoposide 10Ipilimumab 9Everolimus 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Glioblastoma × Sertraline × Clear all
NCT02770378 2021-10-05

A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma

University of Ulm

Phase 1/2 Completed
10 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡